DeepMed Research

ABBVIE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 2013-01-01

Employees: -

Market Cap: $346B

Website: http://www.abbvie.com

Clinical Trials

A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072

Phase 2

Completed

Conditions: HCV
Hepatitis C
Chronic Hepatitis C Infection
Hepatitis C Genotype 1

Interventions: Drug: ABT-450
Drug: ABT-072
Drug: ABT-333
Drug: Ritonavir
Drug: Peginterferon alpha-2a
Other: Placebo
Drug: Ribavirin

First Posted Date: 2010-02-24

Last Posted Date: 2015-01-08

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 74

Registration Number: NCT01074008

Locations: 🇺🇸
Site Reference ID/Investigator# 23370, Anaheim, California, United States
🇺🇸
Site Reference ID/Investigator# 23387, La Jolla, California, United States
🇺🇸
Site Reference ID/Investigator# 23388, Los Angeles, California, United States

and more 23 locations

Study to Evaluate the Effect of Intravenous (IV) Paricalcitol (Zemplar) on Cardiac Morbidity in Patients With Chronic Kidney Disease (CKD) Stage 5 Over 2 Years

Completed

Conditions: Cardiac Morbidity
Chronic Kidney Disease Stage V
Secondary Hyperparathyroidism

First Posted Date: 2010-02-23

Last Posted Date: 2014-07-10

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 67

Registration Number: NCT01073462

Locations: 🇦🇹
Site Reference ID/Investigator# 27482, Vienna, Austria
🇦🇹
Site Reference ID/Investigator# 10981, Vienna, Austria
🇦🇹
Site Reference ID/Investigator# 27487, Innsbruck, Austria

and more 9 locations

Study of Adalimumab in Participants With Peripheral Spondyloarthritis (SpA)

Phase 3

Completed

Conditions: Peripheral Spondyloarthritis

Interventions: Biological: Adalimumab
Biological: Placebo

First Posted Date: 2010-02-09

Last Posted Date: 2021-07-07

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 165

Registration Number: NCT01064856

A Study of ABT-888 in Combination With Carboplatin and Gemcitabine in Subjects With Advanced Solid Tumors

Phase 1

Completed

Conditions: Advanced Solid Tumors

Interventions: Drug: veliparib (ABT-888)
Drug: carboplatin
Drug: gemcitabine

First Posted Date: 2010-02-05

Last Posted Date: 2021-08-02

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 79

Registration Number: NCT01063816

Hydrocodone/Acetaminophen for Acute Pain Following Bunionectomy

Phase 2

Completed

Conditions: Pain

Interventions: Drug: Placebo
Drug: Acetaminophen
Drug: Morphine Extended Release
Drug: Hydrocodone/Acetaminophen Extended Release

First Posted Date: 2009-12-24

Last Posted Date: 2014-04-08

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 250

Registration Number: NCT01038609

Locations: 🇺🇸
Site Reference ID/Investigator# 26302, Austin, Texas, United States
🇺🇸
Site Reference ID/Investigator# 26223, Peoria, Arizona, United States
🇺🇸
Site Reference ID/Investigator# 26303, San Marcos, Texas, United States

and more 1 locations

Safety and Efficacy of Paricalcitol Capsules in Decreasing Serum Parathyroid Hormone Levels in Children Aged 10-16 With Chronic Kidney Disease (CKD)

Phase 3

Completed

Conditions: Chronic Kidney Disease Stage 3 and 4

Interventions: Drug: Paricalcitol
Drug: Placebo

First Posted Date: 2009-11-24

Last Posted Date: 2018-07-02

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 47

Registration Number: NCT01020487

Efficacy and Safety Study of ABT-288 in Subjects With Mild-to-Moderate Alzheimer's Disease

Phase 2

Completed

Conditions: Alzheimer's Disease

Interventions: Drug: ABT-288
Drug: donepezil
Drug: placebo

First Posted Date: 2009-11-24

Last Posted Date: 2018-06-06

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 242

Registration Number: NCT01018875

Locations: 🇺🇦
Site Reference ID/Investigator# 24565, Kherson, Ukraine
🇷🇺
Site Reference ID/Investigator# 22636, Moscow, Russian Federation
🇷🇺
Site Reference ID/Investigator# 22635, St. Petersburg, Russian Federation

and more 18 locations

A Study Evaluating ABT-263 With Erlotinib, ABT-263 With Irinotecan, and ABT-263 Monotherapy in Cancer Subjects

Phase 1

Completed

Conditions: Solid Tumors

Interventions: Drug: ABT-263
Drug: irinotecan (3-week schedule)
Drug: erlotinib
Drug: irinotecan (weekly schedule)

First Posted Date: 2009-11-06

Last Posted Date: 2017-11-20

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 51

Registration Number: NCT01009073

Locations: 🇺🇸
Site Reference ID/Investigator# 37463, Santa Monica, California, United States
🇺🇸
Site Reference ID/Investigator# 36342, Detroit, Michigan, United States
🇺🇸
Site Reference ID/Investigator# 24046, San Antonio, Texas, United States

and more 1 locations

Assessment of the Safety of ABT-308 in Healthy Volunteers and Subjects With Asthma

Phase 1

Completed

Conditions: Asthma

Interventions: Drug: ABT-308
Drug: Placebo

First Posted Date: 2009-09-29

Last Posted Date: 2017-11-21

Lead Sponsor: AbbVie

Target Recruit Count: 47

Registration Number: NCT00986037

Assess the Oral Bioavailability of a New ABT-263 Formulation in Subjects With Cancer

Phase 1

Completed

Conditions: Lymphoid Malignancy
Solid Tumors

Interventions: Drug: ABT-263

First Posted Date: 2009-09-23

Last Posted Date: 2017-11-21

Lead Sponsor: AbbVie

Target Recruit Count: 37

Registration Number: NCT00982566

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy